Cell and Gene Outsourcing

  1. How You And Your CDMO Should Leverage Contamination Control Strategies For Competitive Advantage 9/15/2025

    It is no longer sufficient to just meet compliance requirements; a proactive, risk-based approach to contamination control is now a differentiating factor that enhances operational efficiency and more. For biotech companies evaluating CDMOs, this shift is critical.

  2. August 2025 — CDMO Opportunities And Threats Report 9/11/2025

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

  3. CDMO Hunger Games And The State Of Biotech With Siren Biotechnology's Nicole Paulk, Ph.D. 9/9/2025

    Biotech leader Nicole Paulk, Ph.D., joins “Better Biopharma” to discuss Siren Biotechnology’s switch from plasmids to producer cell lines, CGT funding challenges, and the competition that determined which CDMO won Siren’s business.

  4. Protecting The Foundation Of Biologics With Flexible, Scalable Cell Banking 9/9/2025

    Safeguard your cell banks with secure, compliant storage and streamlined delivery solutions that keep manufacturing on schedule and therapies moving forward.

  5. ATMP Development In 2025: Promise, Pressure, And The Push To Scale 9/9/2025

    Drive the next wave of cell and gene therapy innovation by overcoming operational, funding, and regulatory challenges to deliver life-changing treatments to patients faster.

  6. Built For Speed: How To Deliver Without Compromise 9/9/2025

    Ensure fast, reliable, temperature-controlled logistics with a global infrastructure designed to protect critical biologic materials and keep development programs running smoothly and on schedule.

  7. Take A Virtual Tour Of Our Cell Line Development Centre Of Excellence 9/8/2025

    Explore the advanced capabilities of our Cell Line Development Center in Ulm, Germany. From expert teams to streamlined processes, discover how we support biopharma innovation.

  8. Extractables, Leachables, And Risk: Ensuring Safety In Pharma Manufacturing 9/8/2025

    This session is designed for teams developing new products, optimizing processes, or preparing regulatory submissions, and will provide practical tools for a better approach to E&L management.

  9. Successful Nucleic Acid Extraction: The Linchpin For PCR Bioanalysis 9/8/2025

    Explore nucleic acid extraction approaches for PCR analysis, emphasizing best practices, matrix-specific strategies, validation, normalization, and troubleshooting in cell and gene therapy applications.

  10. Oncology CRO Helping To Bring Cancer Therapies To Patients 9/5/2025

    Niche CRO with a difference

    Catalyst Oncology is a niche oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation therapies to patients in need. Oncology clinical research is complex, demanding, and continually evolving. Bringing effective therapies to proof-of-concept and then to market as fast as possible is our passion because every second counts for patients with cancer and their families.